Ignite Creation Date:
2025-12-25 @ 1:38 AM
Ignite Modification Date:
2025-12-25 @ 11:54 PM
Study NCT ID:
NCT01227694
Status:
COMPLETED
Last Update Posted:
2015-12-11
First Post:
2010-10-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020370', 'term': 'Osteoarthritis, Knee'}, {'id': 'D007718', 'term': 'Knee Injuries'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}, {'id': 'D002357', 'term': 'Cartilage Diseases'}, {'id': 'D010003', 'term': 'Osteoarthritis'}], 'ancestors': [{'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D007869', 'term': 'Leg Injuries'}, {'id': 'D014947', 'term': 'Wounds and Injuries'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 15}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2010-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-11', 'completionDateStruct': {'date': '2013-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2015-12-10', 'studyFirstSubmitDate': '2010-10-22', 'studyFirstSubmitQcDate': '2010-10-22', 'lastUpdatePostDateStruct': {'date': '2015-12-11', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2010-10-25', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2012-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Feasibility of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.', 'timeFrame': '12 months', 'description': 'Feasibility will be assessed by checking the cascade of procedures (from bone marrow extraction to MSC implantation) and confirming the global process is viable.'}, {'measure': 'Safety of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.', 'timeFrame': '12 months', 'description': 'Safety will be assessed by collecting adverse events throughout the experimental phase, including the follow-up at 12 months.'}], 'secondaryOutcomes': [{'measure': 'Efficacy by imaging procedures.', 'timeFrame': '6 months', 'description': 'Articular cartilage changes will be determined by T2-weighted MRI (Cartigram).'}, {'measure': 'Efficacy by imaging procedures.', 'timeFrame': '12 month', 'description': 'Articular cartilage changes will be determined by T2-weighted MRI (Cartigram).'}, {'measure': 'Clinical outcomes.', 'timeFrame': '3 month', 'description': 'Clinical assessment will measure the pain by the visual analogue scale (VAS), the self-reported functional status by Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire (SF-36).'}, {'measure': 'Clinical outcomes.', 'timeFrame': '6 months', 'description': 'Clinical assessment will measure the pain by the visual analogue scale (VAS), the self-reported functional status by Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire (SF-36).'}, {'measure': 'Clinical outcomes.', 'timeFrame': '12 months', 'description': 'Clinical assessment will measure the pain by the visual analogue scale (VAS), the self-reported functional status by Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire (SF-36).'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Cell therapy', 'Regenerative therapy', 'Advance therapy', 'Bone marrow', 'Mesenchymal stem cell', 'Autologous', 'Interventional clinical trial', 'Osteoarthrosis', 'Osteoarthritis', 'Knee'], 'conditions': ['Osteoarthritis, Knee', 'Knee Injuries', 'Joint Diseases', 'Rheumatic Diseases', 'Cartilage Diseases']}, 'referencesModule': {'references': [{'pmid': '25769789', 'type': 'DERIVED', 'citation': 'Vives J, Oliver-Vila I, Pla A. Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments. Cytotherapy. 2015 Aug;17(8):1009-14. doi: 10.1016/j.jcyt.2015.02.002. Epub 2015 Mar 10.'}], 'seeAlsoLinks': [{'url': 'http://www.itrt.es', 'label': 'Institut de Terapia Regenerativa Tissular (ITRT), Barcelona, Spain'}, {'url': 'http://www.bancsang.net', 'label': 'Banc de Sang i Teixits'}]}, 'descriptionModule': {'briefSummary': 'This is a prospective, open-label, single-dose, single-arm phase I-II study in which 15 patients diagnosed with gonarthrosis grade II-III (Kellgren and Lawrence) will enter the study with the primary objective of assessing the feasibility and safety of the knee articular infiltration of autologous bone marrow mesenchymal stem cells (MSC). Secondary objectives are to assess the efficacy by imaging procedures and clinical questionnaires.\n\nMSC obtained from each patient\'s bone marrow will be isolated and expanded "Ex-Vivo" under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, patients will be implanted a single-dose of approximately 40 millions of autologous MSC in the knee by articular injection, and followed up for 12 month. Articular cartilage changes will be determined by T2-weighted MRI (Cartigram) at 6 and 12 month. Clinical assessment will measure the pain by the visual analogue scale (VAS), the self-reported functional status by Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire (SF-36) at 3, 6 and 12 month.\n\nThe working hypothesis proposes that the expected regenerative articular cartilage effect of the MSC will be produced to a measurable degree by imaging procedures and clinical questionnaires.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Gonarthrosis grade II-III of Kellgren and Lawrence assessed by two observers\n2. Chronic knee pain with mechanical characteristics\n3. Absence of local or systemic septic process\n4. Haematological and biochemical laboratory tests without significant alterations that contraindicate treatment.\n5. Informed Consent form signed by the patient\n6. The patient is able to understand the nature of the study\n\nExclusion Criteria:\n\n1. Patients \\< 18 years or legally dependent\n2. Patients \\>65 years\n3. Previous surgery of the knee\n4. Intraarticular treatment in the past 6 month\n5. Knee ligament or meniscus rupture observed by MRI\n6. Any sign of infection\n7. Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab) and syphilis.\n8. Congenital or acquired malformation resulting in significant deformity of the knee and leading to problems in application or evaluation of results.\n9. Overweight expressed as body mass index (BMI) greater than 30.5 (obesity grade II). BMI estimated as mass (kg) / corporal surface (m2).\n10. Pregnant women or intend to become pregnant or breast-feeding\n11. Neoplasia\n12. Immunosuppressive states\n13. Participation in another clinical trial or treatment with a different investigational product within 30 days prior to inclusion in the study.\n14. Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria'}, 'identificationModule': {'nctId': 'NCT01227694', 'briefTitle': 'Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis', 'organization': {'class': 'OTHER', 'fullName': 'Banc de Sang i Teixits'}, 'officialTitle': 'Articular Cartilage Regeneration in Gonarthrosis Grade II and III by Articular Infiltration of Xcel-m-condro-alpha.', 'orgStudyIdInfo': {'id': 'XCEL-M-09-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Autologous MSC knee implantation', 'description': 'Isolation and "Ex-Vivo" expansion of Mesenchymal stem cells (MSC) obtained from each patient\'s bone marrow under GMP conditions at Xcelia-División de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection.', 'interventionNames': ['Other: Autologous MSC knee implantation']}], 'interventions': [{'name': 'Autologous MSC knee implantation', 'type': 'OTHER', 'otherNames': ['Xcel-m-condro-alpha'], 'description': 'Isolation and "Ex-Vivo" expansion of Mesenchymal stem cells (MSC) obtained from each patient\'s bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection.', 'armGroupLabels': ['Autologous MSC knee implantation']}]}, 'contactsLocationsModule': {'locations': [{'zip': '08022', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Centro Medico Teknon-ITRT', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}], 'overallOfficials': [{'name': 'Robert Soler, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Institut de Teràpia Regenerativa Tissular (ITRT)'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Banc de Sang i Teixits', 'class': 'OTHER'}, 'collaborators': [{'name': 'Centro Medico Teknon', 'class': 'OTHER'}, {'name': 'Institut de Terapia Regenerativa Tissular', 'class': 'OTHER'}, {'name': 'Cetir Sant Jordi, S.a..', 'class': 'INDIV'}], 'responsibleParty': {'type': 'SPONSOR'}}}}